May 2, 2018 / 12:23 PM / 6 months ago

BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals

May 2 (Reuters) - Merck KGaA:

* MERCK KGAA, DARMSTADT, GERMANY TO DEVELOP ABITUZUMAB IN METASTATIC COLORECTAL CANCER WITH SFJ PHARMACEUTICALS GROUP

* MERCK KGAA - SFJ PHARMACEUTICALS GROUP TO DEVELOP ABITUZUMAB AS FIRST-LINE TREATMENT FOR MCRC IN COMBINATION WITH ERBITUX AND CHEMOTHERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below